New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia

New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia

Introduction Chagas disease (CD) affects ~7 million people worldwide. Benznidazole (BZN) and nifurtimox (NFX) are the only approved drugs for CD chemotherapy. Although both drugs are highly effective in acute and paediatric infections, their efficacy in adults with chronic CD (CCD) is lower and vari...

Full description

Saved in:
Bibliographic Details
Main Authors: Isabela Ribeiro, Joaquim Gascon, Sergi Sanz, Faustino Torrico, Dolors Soy, Cristina Alonso-Vega, Julio A Urbina, María-Jesús Pinazo, Jimy José Pinto, Virginia R Gonzalez, Gimena Rojas, Lourdes Ortiz, Wilson Garcia, Daniel Lozano, Rosa A Maldonado, Rana Nagarkatti, Alain Debrabant, Alejandro Schijman, M Carmen Thomas, Manuel Carlos López, Katja Michael, Igor C Almeida
Format: Article
Language:English
Published: BMJ Publishing Group 2021-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/12/e052897.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/11/12/e052897.full

Similar Items